Skip to main content
Equibles
ICUI logo

ICUI · Icu Medical Inc · Metrics

Track ICUI — free

Use ICUI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ICUI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$164.61 +3.77 (+2.34%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 19% of revenue

One customer — 19% of revenue (six months ended June 30, 2026)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 19% of revenue (three months ended June 30, 2026)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 19% of revenue (three months ended June 30, 2025)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 18% of revenue (six months ended June 30, 2025)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”
View the 10-Q filed Aug 6, 2026
Market Cap
$4.02B
Shares
25.01M
Volume · Oct 22 53.39K Avg daily vol (3M) 269.06K

ICUI metrics

107 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$160.84
Market cap
$4.02B

Price action

20 metrics
Price change (1W)
-1.1%
Price change (30D)
-0.1%
Price change (3M)
+2.2%
Price change (6M)
+26.3%
Price change (YTD)
+12.7%
Price change (1Y)
+32.9%
Trailing year
Price change (5Y)
-30.2%
52-week high
$187.26
52-week low
$115.45
Change from 52-week high
-14.1%
Change from 52-week low
+39.3%
Annualized volatility
35.3%
Annualized volatility (3M)
34.0%
Beta
1.0
RSI (14D)
47.6
Price vs SMA 50
-3.5%
Price vs SMA 200
+8.6%
Avg volume (3M)
269,058
Relative volume
0.8
Average dollar volume
$45.17M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
25.01M

Valuation

12 metrics
P / E (TTM)
135.2
Trailing earnings · reciprocal yield 0.7%
PEG ratio
—
EV / revenue
2.3×
reciprocal yield 43.6%
EV / EBITDA
18.1×
reciprocal yield 5.5%
EV / EBIT
68.8×
reciprocal yield 1.5%
P / sales
1.9×
reciprocal yield 53.7%
P / book
1.9
reciprocal yield 53.5%
FCF yield
3.8%
TTM · current market cap
Buyback yield
0.1%
P / FCF
26.3
reciprocal yield 3.8%
P / operating cash flow
17.0
reciprocal yield 5.9%
Earnings yield
0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
826.9×
reciprocal yield 0.1%
EV / revenue historical average (3Y)
2.0×
reciprocal yield 50.0%
EV / revenue historical average (5Y)
2.1×
reciprocal yield 48.5%
EV / EBIT historical average (3Y)
82.5×
reciprocal yield 1.2%
EV / EBIT historical average (5Y)
82.5×
reciprocal yield 1.2%
EV / EBITDA historical average (3Y)
16.5×
reciprocal yield 6.0%
EV / EBITDA historical average (5Y)
16.5×
reciprocal yield 6.0%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
39.1%
Operating margin
3.3%
Trailing 12 months
Net margin
1.4%
Gross profit (TTM)
$845.14M
Operating profit (TTM)
$72.06M
Net income (TTM)
$30.09M
Trailing 12 months
Diluted EPS (TTM)
$1.19
FCF margin
7.1%
Effective tax rate
-4,105.4%

Per share

11 metrics
Revenue per diluted share (TTM)
$85.90
Gross profit per diluted share (TTM)
$33.62
Operating profit per diluted share (TTM)
$2.88
EBITDA per diluted share (TTM)
$10.88
Net income per diluted share (TTM)
$1.21
Operating cash flow per diluted share (TTM)
$9.40
Free cash flow per diluted share (TTM)
$6.08
Capital expenditures per diluted share (TTM)
$3.33
R&D per diluted share (TTM)
$3.43
Stock compensation per diluted share (TTM)
$2.19
Book value per share
$86.03

Growth

11 metrics
Revenue growth YoY
+0.5%
Year over year
Net income growth YoY
-46.0%
Revenue (TTM)
$2.16B
Trailing 12 months
EPS growth YoY
-46.9%
Shares change YoY
+1.4%
Year over year · more shares
Revenue CAGR (3Y)
-0.7%
Revenue CAGR (5Y)
+11.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-62.5%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-6.8%

Quality

14 metrics
Return on equity
1.4%
Return on assets
0.8%
Debt / equity
0.6
Current ratio
2.4
EBITDA (TTM)
$273.33M
Free cash flow (TTM)
$152.83M
Quick ratio
1.2
Interest coverage
0.9
Net debt / EBITDA
3.4
Return on invested capital
—
Trailing 12 months
Net cash
−$932.90M
Latest balance sheet
Cash & equivalents
$298.30M
Total assets
$3.97B
Total debt
$1.23B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$236.37M
Capital expenditures (TTM)
$83.54M
R&D (TTM)
$86.32M
SG&A (TTM)
$615.07M
Stock compensation (TTM)
$55.00M
R&D / revenue
4.0%
Stock compensation / revenue
2.5%

Ownership (13F)

9 metrics
13F filers
288
13F filer change QoQ
+11
Institutional ownership
104.5%
Conviction holders (share of 13F filers)
0.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.1%
Holder tenure
13.9
Price vs estimated holder cost
+5.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
28.1%

Short interest

3 metrics
Short interest
6.1%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$6.63M
Insider-sentiment score
16 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 883984 CUSIP 44930G107 13F (30d) 33 filings 33 filers Visit website Investor relations